4-[2-(2,5-dioxo-pyrrolidin-1-yl)-ethoxy]-3-methyl-benzaldehyde | 1443021-38-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-[2-(2,5-dioxo-pyrrolidin-1-yl)-ethoxy]-3-methyl-benzaldehyde
• 英文别名: 4-[2-(2,5-Dioxopyrrolidin-1-yl)ethoxy]-3-methylbenzaldehyde；4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methylbenzaldehyde
• CAS: 1443021-38-2
• 化学式: C₁₄H₁₅NO₄
• 分子量: 261.277
• InChiKey: PKVHBSBQNFPXQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  63.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[2-(2,5-dioxo-pyrrolidin-1-yl)-ethoxy]-3-methyl-benzaldehyde 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 生成 C₂₉H₃₇ClN₂O₅
  参考文献：
  名称：

  二。发现具有β氨基酸核心的一系列新型CXCR3拮抗剂。

  摘要：

  已经鉴定出一系列新的β氨基酸，它们充当CXCR3拮抗剂。以先前优化的在N原子上具有羧酸功能的N，N-二取代苄胺衍生物为起点，研究了具有羧基功能的化合物不与N原子连接的化合物。对人和小鼠肝微粒体的亲和力，代谢稳定性和Caco-2渗透性进行了优化。已鉴定出具有两位数纳摩尔CXCR3亲和力，良好的微粒体稳定性和Caco-2渗透性的化合物。

  DOI：

  10.1016/j.bmcl.2016.10.038

文献信息

• I. Discovery of a novel series of CXCR3 antagonists. Multiparametric optimization of N , N -disubstituted benzylamines
  作者：Imre Bata、Zsuzsanna Tömösközi、Péter Buzder-Lantos、Attila Vasas、Gábor Szeleczky、Sándor Bátori、Veronika Barta-Bodor、László Balázs、György G. Ferenczy

  DOI：10.1016/j.bmcl.2016.10.035

  日期：2016.11

  N,N-Disubstituted benzylamine derivatives have been identified as CXCR3 antagonists. Compounds were optimized to improve affinity and selectivity, to increase metabolic stability in human and mouse liver microsomes, to increase Caco-2 permeability. Optimization was supported by monitoring physico-chemical properties using both experimental and computational means. Several compounds with double-digit

  N，N-二取代的苄胺衍生物已被鉴定为CXCR3拮抗剂。优化化合物以改善亲和力和选择性，以增加人和小鼠肝微粒体的代谢稳定性，以增加Caco-2的通透性。通过使用实验和计算手段监测理化性质来支持优化。已鉴定出具有两位数纳摩尔级CXCR3亲和力，良好的选择性，微粒体稳定性，Caco-2通透性和人肝细胞清除率的化合物。
• Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
  申请人：SANOFI

  公开号：EP2601950A1

  公开（公告）日：2013-06-12

  The present invention relates to compounds of formula 1 that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to the novel intermediates used in the preparation of said compounds.

  本发明涉及公式1的化合物 它们可用作预防性和/或治疗由CXCR3趋化因子异常激活引起的疾病的药物的活性成分。本发明还涉及制备所述化合物的方法、包含所述化合物的药物组合物以及用于制备所述化合物的新中间体。
• [EN] CYCLOALKANE CARBOXYLIC ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'ACIDES CYCLOALCANE CARBOXYLIQUES COMME ANTAGONISTES DU RÉCEPTEUR CXCR3
  申请人：SANOFI SA

  公开号：WO2013084013A1

  公开（公告）日：2013-06-13

  The present invention relates to compounds of formula 1 that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to the novel intermediates used in the preparation of said compounds.

  本发明涉及式1化合物，该化合物作为预防性和/或治疗由CXCR3趋化因子异常激活引起的疾病的药物活性成分是有用的。本发明还进一步涉及制备所述化合物的方法、包含所述化合物的药物组合物以及用于制备所述化合物的新的中间体。
• Substituted B-amino acid derivatives as CXCR3 receptor antagonist
  申请人：SANOFI

  公开号：EP2666769A1

  公开（公告）日：2013-11-27

  The present invention relates to compounds of formula 1 that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to the novel intermediates used in the preparation of said compounds.

  本发明涉及公式1的化合物 它们可用作预防性和/或治疗由CXCR3趋化因子异常激活引起的疾病的药物的活性成分。本发明还涉及制备所述化合物的方法、包含所述化合物的药物组合物以及用于制备所述化合物的新中间体。
• [EN] SUBSTITUTED ß-AMINO ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'ACIDES AMINÉS SS SUBSTITUÉS COMME ANTAGONISTES DU RÉCEPTEUR CXCR3
  申请人：SANOFI SA

  公开号：WO2013174485A1

  公开（公告）日：2013-11-28

  The present invention relates to compounds of formula 1 that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to the novel intermediates used in the preparation of said compounds.

  本发明涉及公式1的化合物，该化合物作为药物活性成分用于预防性和/或治疗由CXCR3趋化因子异常激活引起的疾病。此外，发明还涉及制备所述化合物的方法、包含所述化合物的药物组合物以及用于制备所述化合物的新中间体。